Key points are not available for this paper at this time.
The use of biologics in the treatment of corticosteroid-resistant thyroid eye disease has increased in popularity over the last several years. Here, we describe a patient with progression of symptoms despite multiple courses of corticosteroids, orbital decompression, and teprotumumab. The patient was successfully treated with tocilizumab and remains clinically stable 18 months status post treatment.
Omi Pang (Fri,) studied this question.